Several retrospective studies in MS and NMOSD patients demonstrated an indistinguishable efficacy of extended RTX dosing intervals under CD19+ or CD27+ B-cell level monitoring7,25,27,28,40. The gene discussed is CD27; the disease is myeloid sarcoma.